Cerus Corp (CERS) recently announced their Q3 earnings with a slight miss on EPS and a solid beat on revenue. Although investors should be encouraged by the company’s third-quarter performance, it is the FDA’s final guidance concerning platelet storage and transfusions that should have CERS investors feeling optimistic about the company’s future. Cerus is now in a position to reap the benefits of the FDA's new guidance with its INTERCEPT system.
I intend to review the company’s Q3 earnings and the market’s reaction to the news. In addition, I will go over the